Accepted Manuscript

Title: Letter to the editor re: “Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea” from F Wang and colleagues

Author: J. Bhullar J.A. Drury A.M. Kamal N. Tempest D.K. Hapangama

PII: S0301-2115(16)30873-9
DOI: http://dx.doi.org/doi:10.1016/j.ejogrb.2016.08.025
Reference: EURO 9569

To appear in: EURO

Received date: 25-2-2016
Accepted date: 1-8-2016

Please cite this article as: Bhullar J, Drury JA, Kamal AM, Tempest N, Hapangama D.K. Letter to the editor re: “Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea” from F Wang and colleagues. European Journal of Obstetrics and Gynecology and Reproductive Biology http://dx.doi.org/10.1016/j.ejogrb.2016.08.025

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Letter to the Editor – Brief Communication

Letter to the editor re: “Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea” from F Wang and colleagues

Bhullar J¹, Drury JA¹, Kamal AM¹², Tempest N¹³, Hapangama DK¹³

¹Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, L8 7SS, UK.

²The National Center for Early Detection of Cancer, Oncology Teaching Hospital, Baghdad Medical City, Baghdad, Iraq.

³Liverpool Women’s Hospital NHS Foundation Trust, Liverpool, L8 7SS, UK.
Dear Editor,

We read with interest the article by Wang et al. (1) on the role of CD56 in adenomyosis. The authors, using a mouse monoclonal antibody and immunohistochemistry, reported that there was increased expression of CD56 in ectopic adenomyotic tissue in patients suffering dysmenorrhea when compared to the eutopic tissue and corresponding ectopic adenomyotic tissue from patients without dysmenorrhea.

The mouse monoclonal antibody (MOC31, AbCam #ab187270, Cambridge Science Park, Cambridge, UK) that the authors employed in their work is raised against human epithelial cell adhesion molecule (EpCAM) protein that is known to be expressed by endometrial epithelial cells according to the AbCam website. The expression pattern of EpCAM in the human endometrium is available in the Human Protein Atlas (http://www.proteinatlas.org/ENSG00000119888-EPCAM/tissue/endometrium) and is similar to the figures presented in Wang et al’s manuscript. It is commonly used to isolate endometrial epithelial cells in endometrial studies (2).

CD56, also known as Neural Cell Adhesion Molecule (NCAM), is a well-established marker for uterine Natural Killer (uNK) cells. There is a plethora of papers which describe the immuno-expression pattern of CD56 in the endometrium, and there are validated scoring methods of CD56 expressing uNK cells in the endometrium (3). Figure 1 illustrates CD56 immuno-staining using Novocastra clone 1B6 (Leica Biosystems, Newcastle, UK) in cells within the human eutopic endometrium, and matched ectopic endometriotic lesions and adenomyosis from our group. In accordance with previously published work and the data available on the Human Protein Atlas (http://www.proteinatlas.org/ENSG00000149294-NCAM1/tissue/endometrium) uNK cells were localised within the stroma, while the glandular epithelium remained immuno-negative. We were surprised that there was no mention of uNK cells and the numerous previous publications on endometrial CD56 expression (reviewed in(4)) in the current manuscript. In particular, the absence of reference to previous papers on adenomyosis, for example the 1998 manuscript by a well-known uNK cell research group in the UK was a striking omission (5).

When consulting the Abcam website monoclonal anti-human CD56 antibody clone MOC1 (AbCam, #ab133345) was one of several available antibodies. It seems that the authors could have confused MOC1 with MOC31.

Considering the information presented by the authors on the antibody they used; the known, previously published and well-established expression pattern of EpCAM and CD56 in the human endometrium; and the use of IHC only as a method to confirm the protein of interest by the authors in this manuscript, we conclude that Wang et al.(1) may have misinterpreted the EpCAM protein immuno-localisation for CD56 in their paper. In order to prevent misdirection of scientific readership, we believe that this paper needs to be revised accordingly to confirm whether the conclusions reached by the authors can be supported by the presented data.
References


Figure legend

**Figure 1** Representative micrographs showing CD56 (Novocastra clone 1B6, Leica Biosystems, Newcastle, UK) immunohistochemical staining of human secretory phase eutopic endometrium, endometriosis and adenomyosis lesions. Brown DAB staining shows localisation of CD56 positive uterine Natural Killer cells with blue nuclear haematoxylin counterstain. In all micrographs, CD56 immunostaining is localised to the stromal compartment, while the glandular epithelium remains negative. A; secretory phase eutopic endometrium from a patient with endometriosis. B; Matched peritoneal ectopic endometriotic lesion. C; secretory phase eutopic endometrium from a patient with adenomyosis. D; matched adenomyotic lesion. Magnification x400.
Eutopic endometrium

Endometriosis

A

Adenomyosis

C

B

Ectopic

D